Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEZSCVE:BRMNASDAQ:GRINYSE:RGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.62+0.4%$3.30$3.96▼$12.00$6.48M1.557,305 shs3,624 shsBRMBioRemC$2.17-0.5%C$1.98C$1.67▼C$3.45C$35.58M0.8555,798 shs93,468 shsGRIGRI Bio$1.33-5.0%$1.50$1.10▼$59.34$2.85M-1.68290,934 shs77,259 shsRGCRegal Entertainment Group$604.85+12,345.4%$0.00$3.03▼$950.00$53.35M-0.59265,933 shs2,031 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris+1.69%-3.23%+4.05%+15.76%-46.03%BRMBioRem+2.35%+9.00%+9.55%-11.74%+12.37%GRIGRI Bio+6.06%-2.10%-6.04%-76.63%-97.48%RGCRegal Entertainment Group+0.56%-0.20%+20.28%+4,833.93%+12,940.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEZSAeterna ZentarisN/AN/AN/AN/AN/AN/AN/AN/ABRMBioRemN/AN/AN/AN/AN/AN/AN/AN/AGRIGRI Bio2.0811 of 5 stars3.52.00.00.01.80.01.3RGCRegal Entertainment Group0.2904 of 5 stars0.05.00.00.00.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEZSAeterna Zentaris 0.00N/AN/AN/ABRMBioRem 0.00N/AN/AN/AGRIGRI Bio 3.00Buy$22.001,554.01% UpsideRGCRegal Entertainment Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GRI, BRM, RGC, and AEZS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/27/2025GRIGRI BioAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.004/14/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEZSAeterna Zentaris$2.37M2.73N/AN/A$14.99 per share0.24BRMBioRemC$41.84M0.85C$0.59 per share3.70C$0.63 per share3.44GRIGRI BioN/AN/AN/AN/A$5.22 per shareN/ARGCRegal Entertainment GroupN/AN/AN/AN/A$0.63 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)BRMBioRemC$5.40MC$0.326.70∞N/A12.91%65.14%14.61%N/AGRIGRI Bio-$13.04M-$11.56N/AN/AN/AN/A-289.05%-165.01%8/12/2025 (Estimated)RGCRegal Entertainment Group-$4.30MN/A0.00∞N/AN/AN/AN/AN/ALatest GRI, BRM, RGC, and AEZS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GRIGRI Bio-$4.08-$5.80-$1.72-$5.80N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEZSAeterna ZentarisN/AN/AN/AN/AN/ABRMBioRemN/A6.47%N/AN/AN/AGRIGRI Bio$1.91143.60%N/AN/A N/ARGCRegal Entertainment GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEZSAeterna ZentarisN/A5.945.93BRMBioRem37.471.911.08GRIGRI BioN/A3.103.10RGCRegal Entertainment GroupN/A41.9241.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEZSAeterna Zentaris0.73%BRMBioRem0.47%GRIGRI Bio33.95%RGCRegal Entertainment Group0.13%Insider OwnershipCompanyInsider OwnershipAEZSAeterna Zentaris0.10%BRMBioRem1.90%GRIGRI Bio0.13%RGCRegal Entertainment Group2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataBRMBioRem34,30016.40 millionN/ANot OptionableGRIGRI Bio12.14 million8.92 millionNot OptionableRGCRegal Entertainment GroupN/A13.01 million12.75 millionNot OptionableGRI, BRM, RGC, and AEZS HeadlinesRecent News About These CompaniesRGC Resources: Worth Watching For A Good Entry PointApril 10, 2025 | seekingalpha.comCircle Centre movie theatre, Regal UA, permanently closesNovember 6, 2024 | msn.comRegal UA Circle Centre movie theater closes after 29 yearsNovember 4, 2024 | ibj.com‘Open Enrollment: What You Need to Know,’ with Mindy Morgen of Regal Medical GroupOctober 14, 2024 | sandiegouniontribune.comRegal Cinema and Cinemark upgradesSeptember 24, 2024 | yahoo.comAMC, Regal investing $2.2B to upgrade movie theater experienceSeptember 21, 2024 | msn.comRegal Inks Multiyear Deal With Fandango On Advertising, Concessions SalesAugust 27, 2024 | msn.comSoleil Film's ``All That I Need'' to be Theatrically Released this November in Regal Cinemas, United Artists Theatres and EdwardAugust 17, 2024 | br.advfn.comRegal matriarch 'Mother Lily' Monteverde diesAugust 6, 2024 | philstar.comMother Lily Monteverde, Regal Entertainment matriarch, passes awayAugust 6, 2024 | gmanetwork.comMother Lily Monteverde, Regal Entertainment matriarch and star-maker, dead at 85August 6, 2024 | entertainment.inquirer.netRGC Theatre To Present First Regional Workshop Of GRACE AND THE GHOSTAugust 1, 2024 | broadwayworld.comWhat Is Going on With Regencell Bioscience (RGC) Stock Today?July 23, 2024 | investorplace.comLocal investors buy shuttered Woodway cinema with vision of sports entertainmentJuly 19, 2024 | wacotrib.comEric Bischoff – ‘William Regal Joined WCW When It Was Sh*tstorm’May 27, 2024 | ewrestlingnews.comRegal Hires Exhibition Vet Rob Westerling As SVP U.S. ContentMay 16, 2024 | msn.comOld Regal theater at Music City Mall in Odessa transforming into an Urban Air ParkMay 8, 2024 | msn.comEarly Bird weekend savings arrive at Regal CinemasMay 4, 2024 | msn.comCompany History - Regal Entertainment and ConsultantsMay 1, 2024 | moneycontrol.comThis LGBTQ film fest returns to Mia mi with free Uber rides to theaters for screeningsApril 17, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in Value3 Quality Stocks Trading Near 52-Week LowsBy Gabriel Osorio-Mazilli | May 30, 2025View 3 Quality Stocks Trading Near 52-Week LowsCAVA's Explosive Growth Makes It a Must-Watch StockBy Gabriel Osorio-Mazilli | May 19, 2025View CAVA's Explosive Growth Makes It a Must-Watch StockWhich U.S. Towns See Economic Change First? [2025 Survey]By MarketBeat Staff | June 9, 2025View Which U.S. Towns See Economic Change First? [2025 Survey]GRI, BRM, RGC, and AEZS Company DescriptionsAeterna Zentaris NASDAQ:AEZS$3.62 +0.02 (+0.42%) As of 06/12/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.BioRem CVE:BRMC$2.17 -0.01 (-0.46%) As of 02:18 PM EasternBioRem Inc., a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). It offers biofilters for the removal of odors, H2S, VOCs, and HAPs; and biotrickling filters for applications of high levels of H2S or other water-soluble VOCs. The company also provides multi-stage systems to remove odors from various municipal/urban wastewater treatment processes; biogas desulfurization systems; dry scrubber adsorption systems; and cannabis odor control systems. In addition, it offers biological processes and testing services; media sampling and analysis; system review and inspections; and media replacements and spare parts. The company operates in Canada, the United States, China, and internationally. BioRem Inc. was founded in 1990 and is headquartered in Puslinch, Canada.GRI Bio NASDAQ:GRI$1.33 -0.07 (-4.99%) As of 02:18 PM EasternGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Regal Entertainment Group NYSE:RGCRegal Entertainment Group is an operator of theatre circuits in the United States. As of March 31, 2017, the Company operated 7,262 screens in 559 theatres in 43 states along with Guam, Saipan, American Samoa and the District of Columbia. The Company manages its business under theatre exhibition operations segment. The Company develops, acquires and operates multi-screen theatres primarily in mid-sized metropolitan markets and suburban growth areas of metropolitan markets throughout the United States. The Company operates multi-screen theatres. The Company is the parent company of Regal Entertainment Holdings, Inc. (REH), which is the parent company of Regal Cinemas Corporation (Regal Cinemas) and its subsidiaries. Regal Cinemas' subsidiaries include Regal Cinemas, Inc. (RCI) and its subsidiaries, which include Edwards Theatres, Inc. (Edwards), Regal CineMedia Corporation (RCM) and United Artists Theatre Company (United Artists). More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: Two Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
